Divergent trends in the incidence of end-stage renal disease due to Type 1 and Type 2 diabetes in Europe, Canada and Australia during 1998-2002

Diabetic Medicine

Volumn 23, Issue 12, 2006, Pages 1364-1369

  Stewart, J H ^a   McCredie, Margaret R E ^a   Williams, S M ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

End stage renal disease; Incidence; Temporal trends; Type 1 diabetes; Type 2 diabetes

Indexed keywords

ADULT; ARTICLE; AUSTRALIA; CANADA; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; EUROPE; GEOGRAPHIC DISTRIBUTION; HUMAN; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS;

ADULT; AUSTRALIA; BIAS (EPIDEMIOLOGY); CANADA; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; EUROPE; HUMANS; INCIDENCE; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; PREVALENCE;

EID: 33751215833     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2006.01986.x     Document Type: Article

References (26)

1. Wolfe RA, Held PJ, Hulbert-Shearon TE, Agodoa LYC, Port FK. A critical examination of trends in outcomes over the last decade. Am J Kidney Dis 1998; 32: S9-S15.
2. Stewart JH, McCredie MRE, Williams SM, McDonald SP. Interpreting incidence trends for treated end-stage renal disease: implications for evaluating disease control in Australia. Nephrology 2004; 9: 238-246.
3. US Renal Data System. USRDS 2004 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health. National Institute of Diabetes and Digestive and Kidney Diseases, 2004.
4. Wakai K, Nakai S, Kikuchi K, Iseki K, Miwa N, Masakane I et al. Trends in incidence of end-stage renal disease in Japan, 1983-2000: age-adjusted and age-specific rates by gender and cause. Nephrol Dial Transplant 2004; 19: 2044-2052.
5. Van Dijk PCW, Jager KJ, Stengel B, Gronhagen-Riska C, Feest TG, Briggs JD. Renal replacement therapy for diabetic end-stage renal disease: data from 10 registries in Europe (1991-2000). Kidney Int 2005; 67: 1489-1499.
6. Mogensen CE. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. Br Med J 1982; 285: 685-688.
7. Parving H-H, Hovind P, Rossing K, Andersen S. Evolving strategies for renoprotection: diabetic nephropathy. Curr Opin Nephrol Hypertens 2001; 10: 515-522.
8. Karter AJ, Ferrara A, Liu JY, Moffet HH, Ackerson LM, Selby JV. Ethnic disparities in diabetic complications in an insured population. J Am Med Assoc 2002; 287: 2519-2527.
9. Stewart JH, McCredie MRE, McDonald SP. The incidence of treated end-stage renal disease in New Zealand Maori and Pacific Island people and in Indigenous Australians. Nephrol Dial Transplant 2004; 19: 678-685.
10. Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med 1997; 14: S7-S85.
11. Green A, Gale EAM, Patterson CC, for the EURODAIB ACE Study. Incidence of childhood-onset insulin-dependent diabetes mellitus: the EURODIAB ACE Study Group. Lancet 1992; 339: 905-909.
12. Stengel B, Billon S, van Dijk PCW, Jager KJ, Dekker FW, Simpson K et al. on behalf of the ERA-EDTA Registry Committee. Trends in the incidence of renal replacement therapy for end-stage renal disease in Europe, 1990-99. Nephrol Dial Transplant 2003; 18: 1824-1833.
13. Termorshuizen F, Korevaar JC, Dekker FW, Jager KJ, van Manen JG, Boeschoten EW et al. for the NECOSAD Study Group. Time trends in initiation and dose of dialysis in end-stage renal disease patients in the Netherlands. Nephrol Dial Transplant 2003; 18: 552-558.
14. Finne P, Reunanen A, Stenman S, Groop P-H, Grönhagen-Riska C. Incidence of end-stage renal disease in patients with Type 1 diabetes. J Am Med Assoc 2005; 294: 1782-1787.
15. Fatica RA, Port FK, Young EW. Incidence trends and mortality in end-stage renal disease attributed to renovascular disease in the United States. Am J Kidney Dis 2001; 37: 1184-1190.
16. Olsen S, Mogensen CE. How often is NIDDM complicated with non-diabetic renal disease? An analysis of renal biopsies and the literature. Diabetologia 1996; 39: 1638-1645.
17. Colhoun HM, Lee ET, Bennett PH, Lu M, Keen H, Wang S-L et al. and the WHO Multinational Study Group. Risk factors for renal failure: the WHO multinational study of vascular diseases in diabetes. Diabetologia 2001; 44: S46-S53.
18. Onkamo P, Väänänen S, Karvonen M, Tuomilehto J. Wordwide increase in incidence of Type 1 diabetes - the analysis of data on published incidence trends. Diabetologia 1999; 42: 1395-1403.
19. Harvey JN, Rizvi K, Craney L, Messenger J, Shah R, Meadows PA. Population-based survey and analysis of trends in the prevalence of diabetic nephropathy in Type 1 diabetes. Diabet Med 2001; 18: 998-1002.
20. Dunstan DW, Zimmet PZ, Welborn TA, de Courten MP, Cameron AJ, Sicree RA et al. on behalf of the AusDiab Steering Committee. The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care 2002; 25: 829-834.
21. Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults: the Third National Health and Nutrition Examination Survey, 1988-94. Diabetes Care 1998; 21: 518-524.
22. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. J Am Med Assoc 2003; 289: 76-79.
23. Mokdad AH, Ford ES, Bowman BA, Nelson DE, Engelgau MM, Vinicor F et al. Diabetes trends in the US 1990-98. Diabetes Care 2000; 23: 1278-1283.
24. Fioretto P, Mauer M, Brocco E, Velussi M, Frigato F, Muollo B et al. Patterns of renal injury in NIDDM patients with microalbuminuria. Diabetologia 1996; 39: 1569-1576.
25. Hunsicker LG, Adler S, Caggiula A, England BK, Greene T, Kusek JW et al. for the Modification of Diet in Renal Disease Study Group. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int 1997; 51: 1908-1919.
26. Ruggenenti P, Perna A, Remuzzi G, for the Gruppo Italiano di Studi Epidemiologi in Nefrologia (GISEN). ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN Trial results. J Am Soc Nephrol 2001; 12: 2832-2837.